Response to lebrikizumab in atopic dermatitis patients who failed upadacitinib: 48‑week real‑world outcomes
Description
Supplementary Figure 1. The transition of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) during lebrikizumab treatment in patients with atopic dermatitis switched from upadacitinib 30 mg (n = 15, upper panels) or 15 mg (n = 21, lower panels). Range of box, middle line of box, and lower/upper of whisker represent interquartile, median, and minimum/maximum, respectively. Patients received lebrikizumab 500 mg at weeks 0 and 2, then 250 mg every 2 weeks until week 16, followed by every 4 weeks. TARC, IgE, and LDH decreased until week 48 in both groups. TEC peaked at week 4 in the 30 mg group and at week 12 in the 15 mg group, and then decreased to baseline.